NDRA Endra Life Sciences Inc. - 8-K

Item 2.05 Costs Associated with Exit or Disposal Activities.

On March 25, 2026, ENDRA Life Sciences Inc. (the “Company”)
announced that it has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. In connection
with this revised strategy, on March 19, 2026, the Company reduced the number of its employees in order to reduce cash expenditures and
extend its operational runway. As a result, the Company expects to incur pre-tax cash charges of approximately $51,000 associated with
severance payments to former employees. While the Company will continue to pursue its TAEUS business, this charge reflects the change
in strategic direction for the Company. The Company expects to recognize the severance charges in the first quarter of 2026.

Item 7.01 Regulation FD Disclosure

On March 25, 2026, the Company issued a press release announcing that
it has initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value.

A copy of the press release is included as Exhibit 99.1 hereto and
is incorporated herein by reference.

The information under this Item 7.01, including Exhibit 99.1, shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange
Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the
filings of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such
filing.

Item 9.01 Financial Statements and Exhibits

Number

Description

99.1

Press Release dated March 25, 2026, furnished herewith

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

1